Navigation Links
Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
Date:9/4/2007

- Results Presented at 12th World Conference on Lung Cancer in Seoul -

SOUTH SAN FRANCISCO, Calif., Sept. 4 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today announced that updated results of its Phase 2 clinical trial of picoplatin confirm and extend the previously announced interim data analysis, which demonstrated a survival benefit in patients with recurrent small cell lung cancer (SCLC) who have relapsed within six months of first-line therapy. The company also for the first time announced the median one-year survival rate of 17.6 percent in the Phase 2 population of mostly platinum-refractory and -resistant patients studied in this trial. Picoplatin, the Company's lead product candidate, is currently being evaluated in the pivotal Phase 3 SPEAR (Study of Picoplatin Efficacy After Relapse) trial in SCLC, which is being conducted under a Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA). The SPEAR trial is being conducted in platinum-refractory, -resistant, and -sensitive SCLC patients who have failed or relapsed from initial therapy within six months of initial treatment and is comparing picoplatin treatment with best supportive care to best supportive care alone. The median overall survival is approximately 17 to 22 weeks for patients with recurrent SCLC who are treated with existing second-line chemotherapies, according to the 2007 National Comprehensive Cancer Network practice guidelines.

"These updated Phase 2 data are consistent with earlier studies of picoplatin in this difficult-to-treat patient population and compare favorably with the median survival for the entire populatio
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Poniard Pharmaceuticals Announces Promising Data From Interim Safety Analysis of Phase 1 Combination Trials of Picoplatin in Colorectal and Prostate Cancers
2. Poniard Pharmaceuticals Announces Clinical Data from Picoplatin Phase 2 Small Cell Lung Cancer Trial To Be Presented at American Society of Clinical Oncology Annual Meeting
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
11. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/28/2008)...vember 28 German biotech company,...alized HIV monitoring and,AIDS patient follow-up ... In,the year 2008, 2.5 million patient tests have...hly affordable "CyFlow" system, supporting already... Due to introduction of the,Partec innovation, th...
(Date:11/27/2008)...ity of acute lymphoblastic leukemia relapse cases ...iagnosis , , MEMPHIS, Tenn., Nov. 27 /PRNew...en,s Research Hospital have identified distinctive...ith acute lymphoblastic leukemia (ALL) that cause ... treatments for ALL relapse in children and, ultim...
(Date:11/26/2008)...sity, automation and intelligent clinical applicat...all new level , , CHICAGO, Ill., Nov. 26 /P...ww.siemens.com/healthcare ) highlights the ACUSON...1), the world,s first multi-use, automated volume...Assembly and Annual Meeting of the Radiological So...
(Date:11/25/2008)...rove recovery , , Audio and Web Video Resou...Mayo Clinic News Blog. Please see the bottom of th... Minn., Nov. 25 A Mayo ...on,t think they,re having a stroke -- and as a res...on worsens. The findings appear in the current iss...
Breaking Medicine Technology:German Innovation for HIV/AIDS Diagnostics has Been Used 2.5 Million Times in 2008 2St. Jude Identifies Genomic Causes of a Certain Type of Leukemia Relapse 2St. Jude Identifies Genomic Causes of a Certain Type of Leukemia Relapse 3Siemens Introduces New Standard of Care for Breast Ultrasound 2Siemens Introduces New Standard of Care for Breast Ultrasound 3Siemens Introduces New Standard of Care for Breast Ultrasound 4Siemens Introduces New Standard of Care for Breast Ultrasound 5Do You Know You're Having a Stroke? 2Do You Know You're Having a Stroke? 3Vernalis and Paul Capital Healthcare Sign euro 18 4 Million Financing Agreement 4717 1Vernalis and Paul Capital Healthcare Sign euro 18 4 Million Financing Agreement 4717 2Vernalis and Paul Capital Healthcare Sign euro 18 4 Million Financing Agreement 4717 3Study reveals inaccuracies in studies of cancer treatment 17259 1Study reveals inaccuracies in studies of cancer treatment 17259 2Vitamin D in brain function 2973 1Vitamin D in brain function 2973 2Vitamin D in brain function 2973 3BIO key 28R 29 Receives New Mobile Data Contract Award From Indiana Police Agency 2970 1BIO key 28R 29 Receives New Mobile Data Contract Award From Indiana Police Agency 2970 2BIO key 28R 29 Receives New Mobile Data Contract Award From Indiana Police Agency 2970 3
...product recently approved by FDA for long-term,mai...ta demonstrate,first nebulized formoterol fumarate... powder formoterol, enhanced patient quality of,li... 20, 2007) – Data presented at the,Internati...ATS),demonstrate that Perforomist™ (formoter...
...ship Between Ability to Function and Treatment of ...IANAPOLIS, May 21, 2007 /PRNewswire-FirstCall/ -- ...y disorder (GAD),treated with Cymbalta(R) (duloxet...veryday activities at home, work and in social,sit... in global,functioning were the result of improvem...
Other Medicine Technology:Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 2Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 3Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 4Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 5Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 6Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 7Data Suggest Cymbalta Improved Functioning in Patients with,Generalized Anxiety Disorder 2Data Suggest Cymbalta Improved Functioning in Patients with,Generalized Anxiety Disorder 3Data Suggest Cymbalta Improved Functioning in Patients with,Generalized Anxiety Disorder 4Data Suggest Cymbalta Improved Functioning in Patients with,Generalized Anxiety Disorder 5Data Suggest Cymbalta Improved Functioning in Patients with,Generalized Anxiety Disorder 6
(Date:12/1/2008)...esses common, study shows , , MONDAY, D...e common among young adults in the United States, ...o reach this finding, U.S. researchers analyzed da..., who took part in the National Epidemiologic Surv...dy found that 45.8 percent of the 2,188 college st...
(Date:12/1/2008)...oundation announces the 2008 winners of the Lee C....ecipients, Dr. Gerard Karsenty of the Columbia Uni...nzweig of Rockefeller University received the awar... cure and control of rheumatic diseases. , Dr. ...elopment and function of the skeletal system. A gr...
(Date:12/1/2008)...all/ -- Senetek PLC,(OTC Bulletin Board: SNKTY), ...t of technologies that target the science of healt... specialists in the fields of strategic,developme...ices in Zurich,Bern and Geneva has published a R...ch Report, available in the "Investors" section of...
(Date:12/1/2008)...D) affects as many as one in five of all Americans...ault, war or terrorism. It has emotionally paralyz...lies. , There is no broadly accepted treatment ...er, but thanks to a Tel Aviv University researcher...round the corner. , Prof. Joseph Zohar from the ...
Breaking Medicine News(10 mins):Health News:Few Young Adults Seek Treatment for Psych Disorders 2Health News:Easing the stress of trauma 2
...nt under mandatory isolation since his Greek weddi...erious strain of the disease than initially thoug...ding travels, including seven flights and an overl...obal health alert two months ago when the US Cente...
...s hierarchy issued a decree on the state MENA news...as un-Islamic as the authorities prepared to submi...m of excision is a practice totally banned by Isla... of the extensive damage it causes to women's bodi...
...risers and cosmetic surgery, a compound found in t... skin. In the first study of its kind, a team of...ersity of East Anglia and Dr Paul Kroon at the Ins...hether the skins condition is improved by a compou...
...in northeast France are being analysed to see if t... be fatal to humans, the agriculture ministry said...icion of bird flu. More tests are under way to see...ction with the H5N1 strain,' the ministry said. R...
Other Medicine News:Health News:US Traveler With Deadly TB Has Less Serious Strain 2
...coma Laser System features a patented technique fo...-angle glaucoma. It selectively targets pigmented ...ular pressure. The Selecta II is equipped with a Q...eam of light, which induces the same cell replacem...
Round handle.
Angled shafts, smooth jaws, polished finish.
...signed for insertion of Alcon Acrylic, Chiron/Iola...lenses. The blades are taller and thinner, maximiz... feature prevents lens migration during loading an... spot on the folded lens optic. The special direct...
Medicine Products: